Skip to main content

Adverse event reporting can be found at the bottom of the page.

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Menu

faq hero mobile

FAQ


Autoimmune T1D is no longer considered a solely juvenile disease,1 and screening procedures should reflect this. More than half of new patients are adults,2 and the benefits of screening in the adult population are multifaceted, including the potential to  avoid DKA and prevent misdiagnosis of T2D.2,3,6 
 

The combination of patient education and CGM technology can empower patients and families to understand how to respond to glucose fluctuations effectively,1–4,12 before blood glucose needs more tight control at symptom onset (Stage 3).6,8 This can thereby optimise blood glucose levels from the outset and avoid complications.7–11 
 

Even without symptoms, the autoimmune attack and destruction on beta cells is actively 
and progressively occurring.1–3 Screening allows HCPs to diagnose early-stage autoimmune 
T1D and monitor and educate affected individuals, potentially improving long-term outcomes.4–6 Early identification and monitoring of autoimmune T1D reduces the likelihood of severe emergencies like DKA at diagnosis, which often requires urgent, high-resource intervention.4,5 By reducing the risk of DKA and other complications, screening and monitoring can reduce hospitalisations and lessen the overall demand on emergency and acute care resources4,6

As healthcare moves toward a more preventative model, proactive screening aligns with broader healthcare goals of reducing disease burden and improving patient outcomes.14,15 
 

Although detection of autoantibodies through screening may initially cause stress and anxiety, 
this typically reduces over time. Screening allows time for families to adjust, engage with educational and emotional support and build a support network to allow a smoother transition to Stage 3 autoimmune T1D.1,2 In the TEDDY study, children diagnosed through screening and enrolled in monitoring programmes experienced improved diabetes-specific quality of life and parents reported lower parenting stress compared to community controls outside of screening programmes*3. In a UK study interviewing parents of children screened, screening benefits were reported to outweigh temporary distress, with most 
feeling positive about the experience and reporting willingness to participate again and recommend to others.4
 

Get in Touch with Us

Questions? Leave your details and we'll reach out to you as soon as possible.

Get in touch

MAT-XU-2500770 (v1.0) | October 2025